Synthetic promoters to induce immune-effectors into the tumor microenvironment

Molecular landmarks of tumor hypoxia across cancer types

(2019) Vinayak Bhandari et al.   NATURE GENETICS

Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines

(2019) Sergey V. Kulemzin et al.   BMC Medical Genomics

The global pipeline of cell therapies for cancer

(2019) Jia Xin Yu et al.   NATURE REVIEWS DRUG DISCOVERY

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

(2019) Katrin Mestermann et al.   Science Translational Medicine

T cell engineering for adoptive T cell therapy: safety and receptor avidity

(2019) Elvira D’Ippolito et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Fibroblasts in the Tumor Microenvironment: Shield or Spear?

(2018) Twana Alkasalias et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

The Ebola-Glycoprotein Modulates the Function of Natural Killer Cells

(2018) Avishay Edri et al.   Frontiers in Immunology

Comprehensive network map of interferon gamma signaling

(2018) Mohd Younis Bhat et al.   Journal of Cell Communication and Signaling

Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells

(2017) Iulia Diaconu et al.   MOLECULAR THERAPY

Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?

(2017) Yanqing Huang et al.   Science China-Life Sciences

Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity

(2017) Purnima Bhat et al.   Cell Death & Disease

IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients

(2017) Yunfeng Ma et al.   Advances in Clinical and Experimental Medicine

An oxygen sensitive self-decision making engineered CAR T-cell

(2017) Alexandre Juillerat et al.   Scientific Reports

Quantifying the relative immune cell activation from whole tissue/organ-derived differentially expressed gene data

(2017) Edward Wijaya et al.   Scientific Reports

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

(2016) Gideon Gross et al.   Annual Review of Pharmacology and Toxicology

The hypoxic tumor microenvironment: A driving force for breast cancer progression

(2016) Gregg L. Semenza   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

(2016) Kole T. Roybal et al.   CELL

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts

(2016) M Cartellieri et al.   Blood Cancer Journal

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor

(2015) C.-Y. Wu et al.   SCIENCE

Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome

(2015) Omri Teltsh et al.   Oncotarget

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment

(2014) Daniel Ackerman et al.   TRENDS IN CELL BIOLOGY

The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

(2014) Tessa Gargett et al.   Frontiers in Pharmacology

Chronic Inflammation and Cytokines in the Tumor Microenvironment

(2014) Glauben Landskron et al.   Journal of Immunology Research

Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function

(2013) C. D. Scharer et al.   JOURNAL OF IMMUNOLOGY

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

(2013) Cor HJ Lamers et al.   MOLECULAR THERAPY

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

(2013) Charles G. Drake et al.   Nature Reviews Clinical Oncology

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

(2013) E. Lanitis et al.   Cancer Immunology Research

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

(2012) Scott Wilkie et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Hypoxia-Response Element (HRE)–Directed Transcriptional Regulation of the Rat Lysyl Oxidase Gene in Response to Cobalt and Cadmium

(2012) Song Gao et al.   TOXICOLOGICAL SCIENCES

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

(2011) Antonio Di Stasi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity

(2009) Y. Zhao et al.   JOURNAL OF IMMUNOLOGY